
Perrigo Company plc
PRGO
Updated: 23/09/2026, 11:11:24
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
No summaries found.
- Share price
- $14.31
- Market cap
- $1.98B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Albert A. Manzone
- Employees
- 8,100
- IPO date
- 17/12/1991
- Beta
- 0.536
- Last dividend
- $0.00
- Day range
- $14.16 – $14.45
- 52-week range
- $9.23 – $22.65
- 1-day performance
- 1.27%
- 1-year performance
- 55.04%
- Current drawdown (1Y)
- -36.82%
- CIK
- 0001585364
- CUSIP
- N/A
- ISIN
- IE00BGH1M568
- Created
- 07/12/2025, 13:46:59
- Last update
- 23/09/2026, 11:11:24
Track Perrigo Company plc with an AI analyst
See which prediction-market events move PRGO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Perrigo CEO Ousted Over Personal Conduct
WSJ • STOCK • 08/06/2026, 19:11:00
Perrigo Announces Leadership Transition
PRNewsWire • STOCK • 08/06/2026, 18:18:00
Perrigo: This 11% Yielder Should Cut The Dividend
Seeking Alpha • STOCK • 06/06/2026, 02:40:46
Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y
Zacks Investment Research • STOCK • 07/05/2026, 16:01:13
Perrigo Company plc (PRGO) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 06/05/2026, 18:51:22
Perrigo (PRGO) Q1 Earnings Beat Estimates
Zacks Investment Research • STOCK • 06/05/2026, 10:45:40
Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
PRNewsWire • STOCK • 06/05/2026, 08:30:00
Perrigo Completes Divestiture of Dermacosmetics Business
PRNewsWire • STOCK • 30/04/2026, 18:30:00
Perrigo: Double-Digit Dividend At A Bargain Price
Seeking Alpha • STOCK • 25/03/2026, 17:51:06
Perrigo Company plc (PRGO) Presents at UBS Global Consumer and Retail Conference Transcript
Seeking Alpha • STOCK • 11/03/2026, 16:42:21
PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View
Zacks Investment Research • STOCK • 27/02/2026, 14:10:28
Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations
PRNewsWire • STOCK • 26/02/2026, 07:31:00